Page last updated: 2024-11-02

pipobroman and Atypical Chronic Myeloid Leukemia

pipobroman has been researched along with Atypical Chronic Myeloid Leukemia in 1 studies

Pipobroman: An antineoplastic agent that acts by alkylation.
pipobroman : An N-acylpiperazine that is piperazine in which each of the nitrogens has been acylated by a 3-bromopropionoyl group. An anti-cancer drug.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Andriani, A1
Elli, E1
Trapè, G1
Villivà, N1
Fianchi, L1
Di Veroli, A1
Niscola, P1
Centra, A1
Anaclerico, B1
Montanaro, G1
Martini, V1
Aroldi, A1
Carmosino, I1
Voso, MT1
Breccia, M1
Montanaro, M1
Foà, R1
Latagliata, R1

Other Studies

1 other study available for pipobroman and Atypical Chronic Myeloid Leukemia

ArticleYear
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.
    Hematological oncology, 2019, Volume: 37, Issue:3

    Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Female; Humans; Hydroxyurea; Leuke

2019